Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study
The journal of infectious diseases (Online. University of Chicago Press)/The Journal of infectious diseases